Mostrar el registro sencillo del ítem

dc.contributor.authorMarin-Jimenez, I.
dc.contributor.authorZabana, Y.
dc.contributor.authorRodriguez-Lago, I.
dc.contributor.authorMarin, L.
dc.contributor.authorBarreiro de Acosta, Manuel 
dc.contributor.authorEsteve, M.
dc.contributor.authorGeteii y Geteccu
dc.contributor.authorFerreiro Iglesias, Rocio 
dc.date.accessioned2022-05-05T08:27:39Z
dc.date.available2022-05-05T08:27:39Z
dc.date.issued2020
dc.identifier.issn0210-5705
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32419715es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16669
dc.description.abstractCOVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was described in China in late 2019. There are currently more than three million diagnosed cases, constituting a pandemic which has caused a worldwide crisis. The devastating effects of this infection are due to its highly contagious nature and although mild forms predominate, in absolute values, the rates for severe forms and mortality are very high. The information on the characteristics of the infection in inflammatory bowel disease is of special interest, as these patients have higher attendance at health centres, which may increase their risk of infection. Furthermore, the treatments used to control the inflammatory activity may modify the disease course of COVID-19. The Spanish Working Group on Crohn's Disease and Ulcerative Colitis and the Spanish Nurses Working Group on Inflammatory Bowel Disease have prepared this document as a practical response to some common questions about the treatment of these patients.en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshClinical Laboratory Techniques*
dc.subject.meshDrug Interactions*
dc.subject.meshRisk*
dc.subject.meshVitamin B 12 Deficiency*
dc.subject.meshVitamin B 12*
dc.subject.meshInflammatory Bowel Diseases*
dc.subject.meshDisease Susceptibility*
dc.subject.meshAnxiety*
dc.subject.meshCoronavirus Infections*
dc.subject.meshFamily Characteristics*
dc.subject.meshPneumonia*
dc.subject.meshDiarrhea*
dc.subject.meshImmunosuppressive Agents*
dc.subject.meshFear*
dc.subject.meshBiological Products*
dc.subject.meshHumans*
dc.subject.meshColitis, Ulcerative*
dc.subject.meshEndoscopy*
dc.subject.meshOccupational Diseases*
dc.subject.meshImmunocompromised Host*
dc.titleCOVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)en
dc.typeJournal Articlees
dc.authorsophosMarin-Jimenez, I.;Zabana, Y.;Rodriguez-Lago, I.;Marin, L.;Barreiro-de Acosta, M.;Esteve, M.;Geteii;Geteccu
dc.identifier.doi10.1016/j.gastrohep.2020.05.003
dc.identifier.pmid32419715
dc.identifier.sophos39807
dc.issue.number7es
dc.journal.titleGastroenterologia y Hepatologiaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Hospital da Barbanza::Dixestivoes
dc.page.initial408es
dc.page.final413es
dc.rights.accessRightsopenAccess
dc.subject.decsenfermedades profesionales*
dc.subject.decsdiarrea*
dc.subject.decsenfermedad inflamatoria intestinal*
dc.subject.decsinteracciones farmacológicas*
dc.subject.decsdeficiencia de vitamina B12*
dc.subject.decstécnicas de laboratorio clínico*
dc.subject.decsmiedo*
dc.subject.decssusceptibilidad a enfermedades*
dc.subject.decsansiedad*
dc.subject.decshuésped inmunodeprimido*
dc.subject.decsinmunosupresores*
dc.subject.decsneumonía*
dc.subject.decsproductos biológicos*
dc.subject.decsvitamina B 12*
dc.subject.decscaracterísticas de la familia*
dc.subject.decshumanos*
dc.subject.decsriesgo*
dc.subject.decsendoscopia*
dc.subject.decscolitis ulcerosa*
dc.subject.decsinfecciones por Coronavirus*
dc.subject.keywordHP Barbanzaes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number43es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International